药物性肝损伤的临床评估与预后预测

幸鹭; 王宇; 陶艳艳; 刘成海

doi:10.3969/j.issn.1001-5256.2019.12.039

药物性肝损伤的临床评估与预后预测

DOI: 10.3969/j.issn.1001-5256.2019.12.039

1. 上海中医药大学附属曙光医院肝病研究所
2. 上海市中医临床重点实验室

基金项目:

上海市中医药三年行动计划:中药药源性肝肾损伤的预警模型与示范性系统研究[ZY-(2018-2020)-CCCX-5001]；

详细信息

中图分类号: R575
计量
- 文章访问数: 1273
- HTML全文浏览量: 57
- PDF下载量: 307
- 被引次数: 0
出版历程
- 收稿日期: 2019-07-11
- 出版日期: 2019-12-20

Clinical evaluation and prognosis prediction of drug-induced liver injury

Institute of Liver Diseases,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Research funding:

摘要

摘要: 药物性肝损伤的临床发病广泛,相关危害严重,是肝病治疗与新药研发失败的重要原因。其临床诊断仍是世界性难题,因此探索总结相关临床风险信号,开展临床评估及其预后预测分析,对于预防、诊断与治疗药物性肝损伤均具有重要意义。
- 化学性与药物性肝损伤 /
- 诊断 /
- 预后
Abstract: Drug-induced liver injury( DILI) is commonly seen in clinical practice and may bring serious harm to health. It is an important reason for the failure of liver disease treatment and new drug research and development. The clinical diagnosis of DILI remains a difficult issue in the world,and therefore,exploration of related risk signs and initiation of clinical evaluation and prognosis prediction are of great significance for the prevention,diagnosis,and treatment of DILI.
- chemical and drug induced liver injury /
- diagnosis /
- prognosis

HTML全文

参考文献(60)

[1] WATKINS PB,SEEFF LB. Drug-induced liver injury:Summary of a single topic clinical research conference[J]. Hepatology,2006,43(3):618-631.

[2] LEISE MD,POTERUCHA JJ,TALWALKAR JA. Drug-induced liver injury[J]. Mayo Clin Proc,2014,89(1):95-106.

[3] HAN D,DARA L,WIN S,et al. Regulation of drug-induced liver injury by signal transduction pathways:Critical role of mitochondria[J]. Trends Pharmacol Sci,2013,34(4):243-253.

[4] HYASHI PH. Drug-Induced Liver Injury Network:Causality assessment,criteria,and experience in the United States[J].Int J Mol Sci,2016,17(2):201.

[5] DANAN G,TESCHKE R. RUCAM in drug and herb induced liver injury:The update[J]. Int J Mol Sci,2016,17(1):14.

[6] NAVARRO VJ,BARNHART HX,BONKOVSKY HL,et al. 167Herbal and dietary supplement induced hepatotoxicity in the U. S.[J]. Gastroenterology,2012,142(5):S-41.

[7] BNICHOU C. Criteria of drug-induced liver disorders. Report of an international consensus meeting[J]. J Hepatol,1990,11(2):272-276.

[8] DANAN G,BENICHOU C. Causality assessment of adverse reactions to drugs———I. A novel method based on the conclusions of international consensus meetings:Application to drug-induced liver injuries[J]. J Clin Epidemiol,1993,46(11):1323-1330.

[9] MARIA VA,VICTORINO RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis[J].Hepatology,1997,26(3):664-669.

[10] DAS S,BEHERA SK,XAVIER AS,et al. Agreement among different scales for causality assessment in drug-induced liver injury[J]. Clin Drug Investig,2018,38(3):211-218.

[11] TSUTSUI A,NAKANUMA Y,TAKAGUCHI K,et al. Comparison of liver biopsy findings with the digestive disease week Japan 2004 scale for diagnosis of drug-induced liver injury[J].Mediators Inflamm,2015,2015:913793.

[12] CHALASANI NP,HAYASHI PH,BONKOVSKY HL,et al. ACG Clinical Guideline:The diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol,2014,109(7):950-966; quiz 967.

[13] BHARADWAJ M,ILLING P,THEODOSSIS A,et al. Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex[J]. Annu Rev Pharmacol Toxicol,2012,52:401-431.

[14] CIRULLI ET,NICOLETTI P,ABRAMSON K,et al. A missense variant in PTPN22 is a risk factor for drug-induced liver injury[J]. Gastroenterology,2019,156(6):1707-1716. e2.

[15] LI C,RAO T,CHEN X,et al. HLA-B*35∶01 Allele is a potential biomarker for predicting polygonum multiflorum-induced liver injury in humans[J]. Hepatology,2019,70(1):346-357.

[16] TAJIRI K,SHIMIZU Y. Practical guidelines for diagnosis and early management of drug-induced liver injury[J]. World J Gastroenterol,2008,14(44):6774-6785.

[17] NICOLETTI P,AITHAL GP,BJORNSSON ES,et al. Association of liver injury from specific drugs,or groups of drugs,with polymorphisms in HLA and other genes in a genome-wide association study[J]. Gastroenterology,2017,152(5):1078-1089.

[18] ACKERSON T,AMBERG A,ATZRODT J,et al. Mechanistic investigations of the liver toxicity of the free fatty acid receptor1 agonist fasiglifam(TAK875)and its primary metabolites[J]. J Biochem Mol Toxicol,2019,33(8):e22345.

[19] NORMAN BH,FISHER MJ,SCHIFFLER MA,et al. Identification and mitigation of reactive metabolites of 2-aminoimidazole-containing microsomal prostaglandin E synthase-1 inhibitors terminated due to clinical drug-induced liver injury[J]. J Med Chem,2018,61(5):2041-2051.

[20] IJIRI Y,KATO R,SADAMATSU M,et al. Contributions of caspase-8 and-9 to liver injury from CYP2E1-produced metabolites of halogenated hydrocarbons[J]. Xenobiotica,2018,48(1):60-72.

[21] MARIA GM,MAURIZIO S,MASSIMO G,et al. Optimizing diagnostic approach to drug-induced liver injury[J]. Ital J Med,2018,12(3):180-189.

[22] URRUTIA-MALDONADO E,ALS-PALMER M,MUOZ DE RUEDA P,et al. The relation between activator and inhibitor killer-cell immunoglobulin-like receptors(KIRs)and hepatotoxicity in oncological treatment[J]. Minerva Pediatr,2019.[Epub ahead of print]

[23] KLEINER DE. Histopathological challenges in suspected drug-induced liver injury[J]. Liver Int,2018,38(2):198-209.

[24] Branch of Hepatobiliary Diseases,China Association of Chinese Medicine,Branch of Chinese Patent Medicine,China Association of Chinese Medicine. Guidelines for the clinical management of herb-induced liver injury[J]. J Clin Hepatol,2016,32(5):835-843.(in Chinese)中华中医药学会肝胆病分会，中华中医药学会中成药分会．中草药相关肝损伤临床诊疗指南[J]．临床肝胆病杂志，2016,32(5):835-843.

[25] LEFKOWITCH JH. The pathology of acute liver failure[J]. Adv Anat Pathol,2016,23(3):144-158.

[26] POPPER H,RUBIN E,CARDIOL D,et al. Drug-induced liver disease:A penalty for progress[J]. Arch Intern Med,1965,115:128-136.

[27] HU XQ. Re-discussion on histopathological score of druginduced liver injury[J]. J Hepatol,2014,19(8):577-579.(in Chinese)胡锡琪．药物性肝损伤组织病理学评分再探讨[J]．肝脏，2014,19(8):577-579.

[28] KLEINER DE,CHALASANI NP,LEE WM,et al. Hepatic histological findings in suspected drug-induced liver injury:Systematic evaluation and clinical associations[J]. Hepatology,2014,59(2):661-670.

[29] WANG T,ZHAO X,SHAO C,et al. A proposed pathologic sub-classification of drug-induced liver injury[J]. Hepatol Int,2019,13(3):339-351.

[30] DANIELIDES IC,CONSTANTOULAKIS M,DAIKOS GK. Hepatitis on high dose isoniazid:Reintroduction of the drug in severe tuberculous meningitis[J]. Am J Gastroenterol,1983,78(6):378-380.

[31] MOCTEZUMA-VELZQUEZ C,ABRALDES JG,MONTANO-LOZA AJ. The use of statins in patients with chronic liver disease and cirrhosis[J]. Curr Treat Options Gastroenterol,2018,16(2):226-240.

[32] BELLI C,ZUIN M,MAZZARELLA L,et al. Liver toxicity in the era of immune checkpoint inhibitors:A practical approach[J]. Crit Rev Oncol Hematol,2018,132:125-129.

[33] MITCHELL JR,LONG MW,THORGEIRSSON UP,et al. Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy[J]. Chest,1975,68(2):181-190.

[34] ORTEGA-ALONSO A,ANDRADE RJ. Chronic liver injury induced by drugs and toxins[J]. J Dig Dis,2018,19(9):514-521.

[35] BNICHOU C. Criteria of drug-induced liver disorders. Report of an international consensus meeting[J]. J Hepatol,1990,11(2):272-276.

[36] FONTANA RJ,WATKINS PB,BONKOVSKY HL,et al. Drug-Induced Liver Injury Network(DILIN)prospective study:Rationale,design and conduct[J]. Drug Saf,2009,32(1):55-68.

[37] MEDINA-CALIZ I,ROBLES-DIAZ M,GARCIA-MUOZ B,et al. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury[J]. J Hepatol,2016,65(3):532-542.

[38] TUJIOS SR,LEE WM. Acute liver failure induced by idiosyncratic reaction to drugs:Challenges in diagnosis and therapy[J]. Liver Int,2018,38(1):6-14.

[39] BJRNSSON E,OLSSON R. Outcome and prognostic markers in severe drug-induced liver disease[J]. Hepatology,2005,42(2):481-489.

[40] MENNECOZZI M,LANDESMANN B,PALOSAARI T,et al. Sex differences in liver toxicity-do female and male human primary hepatocytes react differently to toxicants in vitro?[J]. PLo S One,2015,10(4):e0122786.

[41] SCHWINGE D,CARAMBIA A,QUAAS A,et al. Testosterone suppresses hepatic inflammation by the downregulation of IL-17,CXCL-9,and CXCL-10 in a mouse model of experimental acute cholangitis[J]. J Immunol,2015,194(6):2522-2530.

[42] AMACHER DE. Female gender as a susceptibility factor for drug-induced liver injury[J]. Hum Exp Toxicol,2014,33(9):928-939.

[43] ZHU J,SEO JE,WANG S,et al. The Development of a database for herbal and dietary supplement induced liver toxicity[J]. Int J Mol Sci,2018,19(10):2955.

[44] CHALASANI N,REDDY K,FONTANA RJ,et al. Idiosyncratic drug induced liver injury in African-Americans is associated with greater morbidity and mortality compared to caucasians[J]. Am J Gastroenterol,2017,112(9):1382-1388.

[45] ZHU Y,NIU M,WANG JB,et al. Predictors of poor outcomes in 488 patients with herb-induced liver injury[J]. Turk J Gastroenterol,2019,30(1):47-58.

[46] MARTINEZ MA,VUPPALANCHI R,FONTANA RJ,et al. Clinical and histologic features of azithromycin-induced liver injury[J]. Clin Gastroenterol Hepatol,2015,13(2):369-376. e3.

[47] CHALASANI N,BONKOVSKY HL,FONTANA R,et al. Features and outcomes of 899 patients with drug-induced liver injury:The DILIN prospective study[J]. Gastroenterology,2015,148(7):1340-1352. e7.

[48] LEI CJ,WU LP. Clinical types and biochemical indexes in patients with drug-induced liver failure[J/CD]. Chin J Liver Dis(Electr Version),2018,10(1):70-73.(in Chinese)雷创杰，吴柳萍．药物性肝衰竭患者的临床分型及生物化学指标的差异[J/CD]．中国肝脏病杂志(电子版)，2018,10(1):70-73.

[49] VUPPALANCHI R,GOTUR R,REDDY KR,et al. Relationship between characteristics of medications and drug-induced liver disease phenotype and outcome[J]. Clin Gastroenterol Hepatol,2014,12(9):1550-1555.

[50] MEDINA-CALIZ I,GARCIA-CORTES M,GONZALEZ-JIMENEZ A,et al. Herbal and dietary supplement-induced liver injuries in the spanish DILI registry[J]. Clin Gastroenterol Hepatol,2018,16(9):1495-1502.

[51] JING J,TESCHKE R. Traditional Chinese medicine and herb-induced liver injury:Comparison with drug-induced liver injury[J]. J Clin Transl Hepatol,2018,6(1):57-68.

[52] BJRNSSON ES,GUNNARSSON BI,GRNDAL G,et al. Risk of drug-induced liver injury from tumor necrosis factor antagonists[J]. Clin Gastroenterol Hepatol,2015,13(3):602-608.

[53] WEI G,BERGQUIST A,BROOMU,et al. Acute liver failure in Sweden:Etiology and outcome[J]. J Intern Med,2007,262(3):393-401.

[54] REUBEN A. Hy’s law[J]. Hepatology,2004,39(2):574-578.

[55] JEONG R,LEE YS,SOHN C,et al. Model for end-stage liver disease score as a predictor of short-term outcome in patients with drug-induced liver injury[J]. Scand J Gastroenterol,2015,50(4):439-446.

[56] WANG S,SHANGGUAN Y,DING C,et al. Risk factors for acute liver failure among inpatients with anti-tuberculosis drug-induced liver injury[J]. J Int Med Res,2018:300060518811512.

[57] CHURCH RJ,KULLAK-UBLICK GA,AUBRECHT J,et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury:An international collaborative effort[J]. Hepatology,2019,69(2):760-773.

[58] BJRNSSON E,KALAITZAKIS E,OLSSON R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury[J]. Aliment Pharmacol Ther,2007,25(12):1411-1421.

[59] BONKOVSKY HL,BARNHART HX,FOUREAU DM,et al. Cytokine profiles in acute liver injury-Results from the US DrugInduced Liver Injury Network(DILIN)and the Acute Liver Failure Study Group[J]. PLo S One,2018,13(10):e0206389.

[60] CHURCH RJ,KULLAK-UBLICK GA,AUBRECHT J,et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury:An international collaborative effort[J]. Hepatology,2019,69(2):760-773.

施引文献

资源附件(0)

访问统计